Medtronic 2013 Annual Report Download - page 34

75732me_10K.indd 19 7/1/13 6:36 PM
Table of Contents
undertaken pursuant to specific licenses issued by OFAC. The Iranian sales were generally conducted through distributors, some
of whose customers included public hospitals which may be owned or controlled directly or indirectly by the Iranian government.
Certain of these sales were also made to a non-governmental entity which sells to the Iranian Ministry of Health. All activities by
the Company and its non-U.S. subsidiaries with entities in Iran, including certain governmental entities, in the first two quarters
of fiscal year 2013 resulted in approximately $25 million in gross revenue and approximately $16 million in net profits (excluding
selling, general, and administrative expenses and allocations).
Executive Officers of Medtronic
Set forth below are the names and ages of current Section 16(b) executive officers of Medtronic, Inc., as well as information
regarding their positions with Medtronic, their periods of service in these capacities, and their business experiences. There are no
family relationships among any of the officers named, nor is there any arrangement or understanding pursuant to which any person
was selected as an officer.
Omar Ishrak, age 57, has been Chairman and Chief Executive Officer of Medtronic since June 2011. Prior to joining Medtronic,
Mr. Ishrak served as President and Chief Executive Officer of GE Healthcare Systems, a division of GE Healthcare, from 2009
to 2011. Before that, Mr. Ishrak was President and Chief Executive Officer of GE Healthcare Clinical Systems from 2005 to 2008
and President and Chief Executive Officer of GE Healthcare Ultrasound and BMD from 1995 to 2004.
Michael J. Coyle, age 50, has been Executive Vice President and Group President, Cardiac and Vascular Group since December
2009. Prior to that, he served as President of the Cardiac Rhythm Management division at St. Jude from 2001 to 2007, and prior
positions included serving St. Jude as President of the company’s Daig Catheter division and numerous leadership positions at Eli
Lilly & Company.
H. James Dallas, age 54, is a Senior Vice President of the Company. On May 1, 2013, he announced his retirement, effective
September 2, 2013. In April 2008, he was named Senior Vice President, Quality and Operations. Prior to that, he was Senior Vice
President and Chief Information Officer of Medtronic from April 2006 to April 2008. Before joining Medtronic, he held several
executive positions at Georgia Pacific Corporation. Mr. Dallas is a member of the board of directors of KeyCorp.
Gary L. Ellis, age 56, has been Senior Vice President and Chief Financial Officer since May 2005. Prior to that, he was Vice
President, Corporate Controller and Treasurer since October 1999 and Vice President and Corporate Controller from August
1994 to October 1999. Mr. Ellis joined Medtronic in 1989 as Assistant Corporate Controller and was promoted to Vice President
of Finance for Medtronic Europe in 1992, until being named Corporate Controller in 1994. Mr. Ellis is a member of the board
of directors of The Toro Company and past chairman of the American Heart Association.
D. Cameron Findlay, age 53, has been Senior Vice President, General Counsel and Corporate Secretary since August 2009. Prior
to that, Mr. Findlay was Executive Vice President and General Counsel of Aon Corporation from August 2003 to June 2009. Prior
to joining Aon, Mr. Findlay served as the U.S. Deputy Secretary of Labor. Before joining the Labor Department in June 2001, Mr.
Findlay was a partner at the law firm now known as Sidley Austin LLP. Before that, he served in the White House as an aide to
U.S. President George H. W. Bush.
Richard Kuntz, M.D., age 56, has been Senior Vice President and Chief Scientific, Clinical and Regulatory Officer since August
2009. Prior to that, he was Senior Vice President and President, Neuromodulation from October 2005 to August 2009; and prior
to that, he was an interventional cardiologist and Chief of the Division of Clinical Biometrics at Brigham and Women’s Hospital
and Associate Professor of Medicine and Chief Scientific Officer of the Harvard Clinical Research Institute. Mr. Kuntz is a member
of the board of directors of Tengion, Inc.
Geoffrey S. Martha, age 43, has been Senior Vice President of Strategy and Business Development since August 2011. Prior to
joining Medtronic, he served as Managing Director of Business Development at GE Healthcare from April 2007 to July 2011;
General Manager for GE Capital Technology Finance Services from November 2003 to March 2007; Senior Vice President,
Business Development for GE Capital Vendor Financial Services from February 2002 to October 2003; General Manager for GE
Capital Colonial Pacific Leasing from February 2001 to January 2002; and Vice President, Business Development for Potomac
Federal, the GE Capital federal financing investment bank from May 1998 to January 2001.
Christopher J. O’Connell, age 46, has been Executive Vice President and Group President, Restorative Therapies Group since
August 2009. Prior to that, he was Senior Vice President and President, Diabetes from October 2006 to August 2009; President
of Medtronic’s Emergency Response Systems division from May 2005 to October 2006; and Vice President of Sales and Marketing
of Medtronic’s Cardiac Rhythm Disease Management division from November 2001 to May 2005. Mr. O’Connell has served
in various management positions since joining the Company in 1994.
Catherine Szyman, age 46, has been Senior Vice President and Group President of Medtronic Diabetes since November 2012.
Prior to that, she was Senior Vice President and President, Diabetes from August 2009 to November 2012; Senior Vice President,
16